Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

609 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Whole blood gene expression testing for coronary artery disease in nondiabetic patients: major adverse cardiovascular events and interventions in the PREDICT trial.
Rosenberg S, Elashoff MR, Lieu HD, Brown BO, Kraus WE, Schwartz RS, Voros S, Ellis SG, Waksman R, McPherson JA, Lansky AJ, Topol EJ; PREDICT Investigators. Rosenberg S, et al. Among authors: lansky aj. J Cardiovasc Transl Res. 2012 Jun;5(3):366-74. doi: 10.1007/s12265-012-9353-z. Epub 2012 Mar 7. J Cardiovasc Transl Res. 2012. PMID: 22396313 Free PMC article.
Two-year follow-up after intracoronary gamma radiation therapy.
Condado JA, Waksman R, Calderas C, Saucedo J, Lansky A. Condado JA, et al. Cardiovasc Radiat Med. 1999 Jan-Mar;1(1):30-5. doi: 10.1016/s1522-1865(98)00014-6. Cardiovasc Radiat Med. 1999. PMID: 11272353 Clinical Trial.
Ischemic and bleeding outcomes in women treated with bivalirudin during percutaneous coronary intervention: a subgroup analysis of the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE)-2 trial.
Chacko M, Lincoff AM, Wolski KE, Cohen DJ, Bittl JA, Lansky AJ, Tsuchiya Y, Betriu A, Yen MH, Chew DP, Cho L, Topol EJ. Chacko M, et al. Among authors: lansky aj. Am Heart J. 2006 May;151(5):1032.e1-7. doi: 10.1016/j.ahj.2006.02.012. Am Heart J. 2006. PMID: 16644331
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease.
Stone GW, Rizvi A, Newman W, Mastali K, Wang JC, Caputo R, Doostzadeh J, Cao S, Simonton CA, Sudhir K, Lansky AJ, Cutlip DE, Kereiakes DJ; SPIRIT IV Investigators. Stone GW, et al. Among authors: lansky aj. N Engl J Med. 2010 May 6;362(18):1663-74. doi: 10.1056/NEJMoa0910496. N Engl J Med. 2010. PMID: 20445180 Free article. Clinical Trial.
Comparison of everolimus-eluting and paclitaxel-eluting coronary stents in patients undergoing multilesion and multivessel intervention: the SPIRIT III (A Clinical Evaluation of the Investigational Device XIENCE V Everolimus Eluting Coronary Stent System [EECSS] in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) and SPIRIT IV (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With De Novo Native Coronary Artery Lesions) randomized trials.
Kereiakes DJ, Sudhir K, Hermiller JB, Gordon PC, Ferguson J, Yaqub M, Sood P, Su X, Yakubov S, Lansky AJ, Stone GW. Kereiakes DJ, et al. Among authors: lansky aj. JACC Cardiovasc Interv. 2010 Dec;3(12):1229-39. doi: 10.1016/j.jcin.2010.09.014. JACC Cardiovasc Interv. 2010. PMID: 21232716 Free article.
609 results